Deals in Depth: August 2011
Executive Summary
Merck is tasking Zymeworks' Azymetric platform for bi-specific cancer and autoimmune antibodies in a $187 million alliance. Par paid $410 million for generics company Anchen, while Baxter acquired additional medical delivery systems through its $380 million purchase of Baxa. With $334 million raised, device financing surpassed biopharma's $224 million in fundraising in August, thanks to large late-stage rounds from NeuroPace, Restoration Robotics and Entellus.